JP2006525995A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006525995A5 JP2006525995A5 JP2006507483A JP2006507483A JP2006525995A5 JP 2006525995 A5 JP2006525995 A5 JP 2006525995A5 JP 2006507483 A JP2006507483 A JP 2006507483A JP 2006507483 A JP2006507483 A JP 2006507483A JP 2006525995 A5 JP2006525995 A5 JP 2006525995A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- cells
- therapeutic agent
- antibody
- allogeneic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004027 cell Anatomy 0.000 claims 12
- 239000012830 cancer therapeutic Substances 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 102000004127 Cytokines Human genes 0.000 claims 6
- 108090000695 Cytokines Proteins 0.000 claims 6
- 230000000735 allogeneic effect Effects 0.000 claims 6
- 229940030156 cell vaccine Drugs 0.000 claims 6
- 230000000981 bystander Effects 0.000 claims 5
- 108010029697 CD40 Ligand Proteins 0.000 claims 3
- 102100032937 CD40 ligand Human genes 0.000 claims 3
- 102000006992 Interferon-alpha Human genes 0.000 claims 3
- 108010047761 Interferon-alpha Proteins 0.000 claims 3
- 229940111134 coxibs Drugs 0.000 claims 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims 1
- 102000004473 OX40 Ligand Human genes 0.000 claims 1
- 108010042215 OX40 Ligand Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Claims (20)
- 癌である対象の治療に使用する医薬組成物の製造における、サイトカイン発現細胞ワクチン、並びに、抗ＣＴＬＡ４抗体、抗４−１ＢＢ抗体、インターフェロンα、ドセタキセル、パクリタキセル、ＣＯＸ−２阻害剤、抗ＣＤ４０抗体又はＣＤ４０リガンド、抗ＯＸ４０抗体又はＯＸ４０リガンド、及び熱ショックタンパク質から成る群から選ばれる少なくとも一つの追加の癌治療剤の使用。
- サイトカイン発現細胞ワクチンがＧＭ−ＣＳＦを発現する、請求項１記載の使用。
- サイトカイン発現細胞ワクチンの細胞が該対象に対して自己である、請求項１又は２記載の使用。
- サイトカイン発現細胞ワクチンの細胞が該対象に対して同種異系である、請求項１又は２記載の使用。
- サイトカイン発現細胞ワクチンの細胞が該対象に対してバイスタンダー細胞である、請求項１又は２記載の使用。
- サイトカイン発現細胞ワクチンの細胞が放射線照射によって増殖不能とされる、請求項１〜５のいずれか一項に記載の使用。
- 対象がヒトである、請求項６記載の使用。
- 癌が前立腺癌又は非小細胞肺癌である、請求項６記載の使用。
- 同種異系細胞が前立腺癌株、非小細胞肺癌株、及び膵臓癌株から成る群から選ばれる腫瘍細胞株である、請求項４，６又は７記載の使用。
- 少なくとも一つの追加の癌治療剤が抗ＣＴＬＡ４抗体を含む、請求項１〜９のいずれか一項に記載の使用。
- 少なくとも一つの追加の癌治療剤が抗４−１ＢＢ抗体を含む、請求項１〜９のいずれか一項に記載の使用。
- 少なくとも一つの追加の癌治療剤がインターフェロンαを含む、請求項１〜９のいずれか一項に記載の使用。
- 少なくとも一つの追加の癌治療剤がドセタキセル又はパクリタキセルを含む、請求項１〜９のいずれか一項に記載の使用。
- 少なくとも一つの追加の癌治療剤がＣＯＸ−２阻害剤を含む、請求項１〜９のいずれか一項に記載の使用。
- ＣＯＸ−２阻害剤がセレコキシブである、請求項１４記載の使用。
- 少なくとも一つの追加の癌治療剤が抗ＣＤ４０抗体又はＣＤ４０リガンドである、請求項１〜９のいずれか一項に記載の使用。
- 少なくとも一つの追加の癌治療剤が細胞によって発現され、該細胞が自己、同種異系、又はバイスタンダー細胞である、請求項１〜９のいずれか一項に記載の使用。
- 自己、同種異系、又はバイスタンダー細胞が放射線照射によって増殖不能とされる、請求項１７記載の使用。
- 自己、同種異系、又はバイスタンダー細胞がインターフェロンαを発現する、請求項１８記載の使用。
- 自己、同種異系、又はバイスタンダー細胞がＣＤ４０リガンドを発現する、請求項１８記載の使用。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/404,662 US20040197312A1 (en) | 2003-04-02 | 2003-04-02 | Cytokine-expressing cellular vaccine combinations |
| PCT/US2004/008846 WO2004093831A2 (en) | 2003-04-02 | 2004-03-24 | Cytokine-expressing cellular vaccine combinations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011175553A Division JP5607000B2 (ja) | 2003-04-02 | 2011-08-11 | サイトカイン発現細胞ワクチンの組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006525995A JP2006525995A (ja) | 2006-11-16 |
| JP2006525995A5 true JP2006525995A5 (ja) | 2007-05-24 |
Family
ID=33096962
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006507483A Withdrawn JP2006525995A (ja) | 2003-04-02 | 2004-03-24 | サイトカイン発現細胞ワクチンの組み合わせ |
| JP2011175553A Expired - Fee Related JP5607000B2 (ja) | 2003-04-02 | 2011-08-11 | サイトカイン発現細胞ワクチンの組み合わせ |
| JP2014084319A Pending JP2014169299A (ja) | 2003-04-02 | 2014-04-16 | サイトカイン発現細胞ワクチンの組み合わせ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011175553A Expired - Fee Related JP5607000B2 (ja) | 2003-04-02 | 2011-08-11 | サイトカイン発現細胞ワクチンの組み合わせ |
| JP2014084319A Pending JP2014169299A (ja) | 2003-04-02 | 2014-04-16 | サイトカイン発現細胞ワクチンの組み合わせ |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20040197312A1 (ja) |
| EP (3) | EP1608321A4 (ja) |
| JP (3) | JP2006525995A (ja) |
| CA (1) | CA2519563A1 (ja) |
| WO (1) | WO2004093831A2 (ja) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110142887A1 (en) * | 2009-12-15 | 2011-06-16 | Immunovative Therapies Ltd. | Methods and compositions for liquidation of tumors |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| US7297204B2 (en) | 2004-02-18 | 2007-11-20 | Meadwestvaco Corporation | Water-in-oil bituminous dispersions and methods for producing paving compositions from the same |
| JP2006265155A (ja) * | 2005-03-23 | 2006-10-05 | Link Genomics Kk | 癌の免疫療法 |
| US7976852B2 (en) * | 2005-04-26 | 2011-07-12 | Eisai R&D Management Co., Ltd. | Compositions and methods for cancer immunotherapy |
| MY147379A (en) | 2005-12-02 | 2012-11-30 | Sinai School Medicine | Chimeric viruses presenting non-native surface proteins and uses thereof |
| US20100015143A1 (en) * | 2006-03-22 | 2010-01-21 | Tracy Hussell | Compositions and Methods Relating to Modulation of Immune System Components |
| JP6092497B2 (ja) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物 |
| US7919079B2 (en) * | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
| AU2007248628B2 (en) | 2006-05-03 | 2013-02-07 | The Regents Of The University Of Colorado, A Body Corporate | CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity |
| EP2094268A2 (en) * | 2006-05-26 | 2009-09-02 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
| AU2007307080B2 (en) * | 2006-10-06 | 2014-01-09 | Bavarian Nordic A/S | Methods for treating cancer with MVA |
| US20080181874A1 (en) * | 2007-01-29 | 2008-07-31 | Alexander Kharazi | Cell composition and method for treating cancer |
| WO2009014708A2 (en) * | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| US8425897B2 (en) * | 2007-08-30 | 2013-04-23 | Immutep S.A. | Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use |
| ES2336873B1 (es) * | 2007-11-07 | 2011-01-24 | Proyecto De Biomedicina Cima, S.L. | Composicion farmaceutica para el tratamiento de cancer. |
| DK2257301T3 (da) | 2008-03-03 | 2014-04-28 | Univ Miami | Immunterapi baseret på allogene cancerceller. |
| US8591881B2 (en) | 2009-02-05 | 2013-11-26 | Mount Sinai School Of Medicine | Chimeric Newcastle disease viruses and uses thereof |
| BR112012027745A2 (pt) * | 2010-04-27 | 2017-01-10 | Univ Johns Hopkins | método e composição imunogênica para tratamento de neoplásia |
| US9572894B2 (en) * | 2010-10-18 | 2017-02-21 | The University Of Iowa Research Foundation | Biodegradable particulate formulations |
| CN103611163A (zh) | 2011-09-05 | 2014-03-05 | 韩美科学株式会社 | 一种包含干扰素α-缀合物的抗癌用药物组合物 |
| JP2014527983A (ja) * | 2011-09-19 | 2014-10-23 | ザ ジョンズ ホプキンス ユニバーシティー | 癌免疫療法 |
| EP2858722B8 (en) * | 2012-06-08 | 2018-02-21 | Aduro BioTech, Inc. | Compostions and methods for cancer immunotherapy |
| KR20150038066A (ko) * | 2012-07-30 | 2015-04-08 | 알렉스 와 힌 영 | 종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템 |
| SG10201802982WA (en) | 2013-03-14 | 2018-06-28 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
| WO2014157692A1 (ja) | 2013-03-29 | 2014-10-02 | 大日本住友製薬株式会社 | Ｗｔ１抗原ペプチドコンジュゲートワクチン |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| WO2015095811A2 (en) | 2013-12-20 | 2015-06-25 | The Board Institute Inc. | Combination therapy with neoantigen vaccine |
| JP6857498B2 (ja) | 2014-02-27 | 2021-04-14 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 癌を処置するための併用方法 |
| WO2015131176A1 (en) * | 2014-02-28 | 2015-09-03 | Podack Eckhard R | Compositions, methods, and kits for treatment of cancer |
| CA2958771A1 (en) * | 2014-09-08 | 2016-03-17 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer |
| WO2016060105A1 (ja) * | 2014-10-15 | 2016-04-21 | 住友化学株式会社 | リチウム二次電池用正極活物質、リチウム二次電池用正極及びリチウム二次電池 |
| EP3757211A1 (en) | 2014-12-19 | 2020-12-30 | The Broad Institute, Inc. | Methods for profiling the t-cell-receptor repertoire |
| WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
| KR20170109582A (ko) | 2015-02-06 | 2017-09-29 | 히트 바이오로직스, 인코퍼레이티드 | 벡터 공동 발현 백신 및 공동 자극 분자 |
| MX2017011374A (es) | 2015-03-06 | 2018-01-23 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
| WO2016154684A1 (en) * | 2015-04-02 | 2016-10-06 | Cancure Limited | Agents and compositions for eliciting an immune response |
| AU2016256911B2 (en) | 2015-05-07 | 2022-03-31 | Agenus Inc. | Anti-OX40 antibodies and methods of use thereof |
| KR20180010229A (ko) | 2015-05-20 | 2018-01-30 | 더 브로드 인스티튜트, 인코퍼레이티드 | 공유 신생항원 |
| CA2986367A1 (en) * | 2015-05-20 | 2016-11-24 | Sumitomo Dainippon Pharma Co., Ltd. | Combination use of wt1 antigen peptide and immunomodulator |
| SG10202008304TA (en) | 2015-05-29 | 2020-10-29 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof |
| KR20180027563A (ko) | 2015-07-13 | 2018-03-14 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린 조성물 |
| CN108883173B (zh) | 2015-12-02 | 2022-09-06 | 阿吉纳斯公司 | 抗体和其使用方法 |
| AU2016369519B2 (en) | 2015-12-16 | 2023-04-20 | Gritstone Bio, Inc. | Neoantigen identification, manufacture, and use |
| US10912748B2 (en) | 2016-02-08 | 2021-02-09 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| US11497781B2 (en) | 2016-03-10 | 2022-11-15 | Cg Oncology, Inc. | Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor |
| KR20190015361A (ko) | 2016-06-06 | 2019-02-13 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증을 줄이는 조성물 및 방법 |
| WO2017223090A1 (en) * | 2016-06-21 | 2017-12-28 | The Trustees Of Columbia University In The City Of New York | Whole-cell based vaccine against zika virus |
| CA3040123A1 (en) | 2016-10-11 | 2018-04-19 | University Of Miami | Vectors and vaccine cells for immunity against zika virus |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| JP2020514412A (ja) | 2017-02-01 | 2020-05-21 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 好中球減少症の低減方法 |
| CA3058938A1 (en) | 2017-04-04 | 2018-10-11 | Heat Biologics, Inc. | Intratumoral vaccination |
| CN110573624A (zh) | 2017-04-14 | 2019-12-13 | 永恒生物科技股份有限公司 | 治疗膀胱癌的方法 |
| AU2018348165A1 (en) | 2017-10-10 | 2020-05-21 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
| JP2021503897A (ja) | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | 新生抗原のためのジャンクションエピトープ提示の低減 |
| CN112135614A (zh) | 2018-01-24 | 2020-12-25 | 大连万春布林医药有限公司 | 通过施用普那布林减少血小板减少症的组合物和方法 |
| EP3820485A4 (en) * | 2018-05-15 | 2022-05-11 | The Brigham & Women's Hospital, Inc. | COMPOSITIONS AND METHODS RELATED TO TUMOR CELL KILLERS AND VACCINES |
| CN112638388A (zh) * | 2018-08-16 | 2021-04-09 | 大连万春布林医药有限公司 | 刺激免疫反应的方法和组合物 |
| WO2021076811A1 (en) * | 2019-10-15 | 2021-04-22 | Moderna TX, Inc. | Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease |
| TWI776276B (zh) * | 2019-11-13 | 2022-09-01 | 中國醫藥大學 | 異種組織細胞組合物治療癌症之用途 |
| IL293446A (en) | 2019-12-03 | 2022-07-01 | Neuvogen Inc | Tumor cell vaccines |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5078996A (en) * | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
| US5098702A (en) * | 1986-04-09 | 1992-03-24 | Cetus Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
| CA1339354C (en) * | 1988-09-01 | 1997-08-26 | The Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
| US6303121B1 (en) * | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
| US5665577A (en) * | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| US5266491A (en) * | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
| JP3051411B2 (ja) * | 1989-03-14 | 2000-06-12 | 持田製薬株式会社 | 新規ｄｎａならびにそれを含有する発現プラスミド |
| US5436146A (en) * | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US5981276A (en) * | 1990-06-20 | 1999-11-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| CA2091346C (en) | 1990-09-14 | 2007-04-24 | Philip Frost | Methods and compositions for genetic therapy and potentiation of anti-tumor immunity |
| US5674486A (en) * | 1991-06-25 | 1997-10-07 | San Diego Regional Cancer Center | Cancer immunotherapy with carrier cells |
| US5904920A (en) * | 1991-10-04 | 1999-05-18 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
| US5637483A (en) * | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
| US7211259B1 (en) * | 1993-05-07 | 2007-05-01 | Immunex Corporation | 4-1BB polypeptides and DNA encoding 4-1BB polypeptides |
| AU6827094A (en) * | 1993-05-07 | 1994-12-12 | Immunex Corporation | Cytokine designated 4-1bb ligand and human receptor that binds thereto |
| US6506604B2 (en) * | 1993-06-11 | 2003-01-14 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| US5872005A (en) * | 1994-11-03 | 1999-02-16 | Cell Genesys Inc. | Packaging cell lines for adeno-associated viral vectors |
| ATE226641T1 (de) * | 1995-04-08 | 2002-11-15 | Lg Chemical Ltd | Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie |
| US6093570A (en) * | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6040183A (en) * | 1995-06-07 | 2000-03-21 | University Of North Carloina At Chapel Hill | Helper virus-free AAV production |
| US6033674A (en) * | 1995-12-28 | 2000-03-07 | Johns Hopkins University School Of Medicine | Method of treating cancer with a tumor cell line having modified cytokine expression |
| US6805869B2 (en) * | 1996-06-12 | 2004-10-19 | Shanghai Cp Guojian Pharmaceutical Co., Ltd. | Cellular vaccines and immunotherapeutics and methods for their preparation |
| IL129138A0 (en) * | 1996-10-11 | 2000-02-17 | Bristol Myers Squibb Co | Methods and compositions for immunomodulation |
| ES2224375T3 (es) | 1997-04-14 | 2005-03-01 | Cell Genesys, Inc. | Metodos para aumentar la eficacia del producto de aav recombinante. |
| US5891432A (en) * | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
| US6037177A (en) * | 1997-08-08 | 2000-03-14 | Cell Genesys, Inc. | Method for increasing the efficiency of recombinant AAV production |
| US5994136A (en) * | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| ATE264911T1 (de) * | 1998-02-02 | 2004-05-15 | Univ Johns Hopkins Med | Eine universelle immunmodulatorische cytokin- expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen |
| WO2000026676A1 (en) * | 1998-11-03 | 2000-05-11 | Cell Genesys, Inc. | Cancer-associated antigens and methods of their identification |
| KR20000034847A (ko) * | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
| ATE397457T1 (de) * | 1998-12-03 | 2008-06-15 | Univ California | Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen |
| US20030035790A1 (en) * | 1999-01-15 | 2003-02-20 | Shu-Hsia Chen | Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject |
| AU5458500A (en) | 1999-06-02 | 2000-12-18 | Cell Genesys, Inc. | Regulation of systemic immune responses utilizing cytokines and antigens |
| US7408041B2 (en) * | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| CN1168740C (zh) * | 2001-04-04 | 2004-09-29 | 上海美恩生物技术有限公司 | 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途 |
| IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| AU2002335973A1 (en) * | 2001-10-23 | 2003-05-06 | Centre For Translational Research In Cancer | A synthetic chimeric fusion protein with immuno-therapeutic uses |
| US7439042B2 (en) * | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| US7176022B2 (en) * | 2002-12-20 | 2007-02-13 | Cell Genesys, Inc. | Directly injectable formulations which provide enhanced cryoprotection of cell products |
-
2003
- 2003-04-02 US US10/404,662 patent/US20040197312A1/en not_active Abandoned
-
2004
- 2004-03-24 CA CA002519563A patent/CA2519563A1/en not_active Abandoned
- 2004-03-24 US US10/807,449 patent/US20050002916A1/en not_active Abandoned
- 2004-03-24 EP EP04759735A patent/EP1608321A4/en not_active Withdrawn
- 2004-03-24 EP EP12191778A patent/EP2574346A1/en not_active Withdrawn
- 2004-03-24 EP EP20140193001 patent/EP2859901A1/en not_active Ceased
- 2004-03-24 WO PCT/US2004/008846 patent/WO2004093831A2/en active Search and Examination
- 2004-03-24 JP JP2006507483A patent/JP2006525995A/ja not_active Withdrawn
-
2011
- 2011-07-12 US US13/180,644 patent/US20120034242A1/en not_active Abandoned
- 2011-08-11 JP JP2011175553A patent/JP5607000B2/ja not_active Expired - Fee Related
-
2014
- 2014-04-16 JP JP2014084319A patent/JP2014169299A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006525995A5 (ja) | ||
| Tai et al. | Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells | |
| AU2015219495B2 (en) | Disease therapy by inducing immune response to Trop-2 expressing cells | |
| NZ704295A (en) | Compositions and methods for the treatment of infections and tumors | |
| JP2017516775A5 (ja) | ||
| RU2019114963A (ru) | Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo | |
| WO2004113571A3 (en) | Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis | |
| WO2007092939A8 (en) | Antigenic gm-csf peptides and antibodies to gm-csf | |
| Watkins-Yoon et al. | CTX-8573, an innate-cell engager targeting BCMA, is a highly potent multispecific antibody for the treatment of multiple myeloma | |
| DE69939837D1 (de) | Neue krebsbehandlung | |
| Pai et al. | Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels | |
| JP2019532047A5 (ja) | ||
| JP2014523398A5 (ja) | ||
| Kebriaei et al. | Adoptive therapy using sleeping beauty gene transfer system and artificial antigen presenting cells to manufacture T cells expressing CD19-specific chimeric antigen receptor | |
| Liu et al. | Superior antitumor efficacy of IFN-α2b-incorporated photo-cross-linked hydrogels combined with T cell transfer and low-dose irradiation against gastric cancer | |
| Devaraja | Current prospects of molecular therapeutics in head and neck squamous cell carcinoma | |
| Galvan Morales et al. | Overview of new treatments with immunotherapy for breast cancer and a proposal of a combination therapy | |
| WO2011056566A3 (en) | Compounds and methods for treatment of cancer | |
| Ruella et al. | Novel chimeric antigen receptor T cells for the treatment of Hodgkin lymphoma | |
| Wang et al. | Cord blood-derived cytokine-induced killer cellular therapy plus radiation therapy for esophageal cancer: a case report | |
| Wang et al. | Injectable versatile liquid-solid transformation implants alliance checkpoint blockade for magnetothermal dynamic-immunotherapy | |
| Fischer et al. | RIG-I-induced type I IFNs promote regeneration of the intestinal stem cell compartment during acute tissue damage | |
| Bardet et al. | Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy | |
| Arai et al. | Enhanced expression of CXCR4 facilitates the trafficking of anti-C-kit chimeric antigen receptor (CAR) T cells to bone marrow and achieves effective donor stem cell engraftment | |
| Das et al. | Blockade of IL-23 Signaling Results in Targeted Protection of the Colon and Allows for Separation of Graft Versus Host and Graft Versus Leukemia Effects. |